Therapies for Macular Edema Associated with Branch Retinal Vein Occlusion: A Report by the American Academy of Ophthalmology

Ophthalmology

Volumn 124, Issue 9, 2017, Pages 1412-1423

  Ehlers, Justis P ^a   Kim, Stephen J ^b   Yeh, Steven ^c   Thorne, Jennifer E ^d   Mruthyunjaya, Prithvi ^e   Schoenberger, Scott D ^f   Bakri, Sophie J ^g  

^a LERNER RESEARCH INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e STANFORD UNIVERSITY   (United States)

^f Retina Physicians and Surgeons   (United States)

^g MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DEXAMETHASONE; RANIBIZUMAB; TRIAMCINOLONE; ANGIOGENESIS INHIBITOR; DRUG IMPLANT;

ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CHORIORETINAL ANASTOMOSIS; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; HEMODILUTION; HUMAN; INTRAVITREAL IMPLANT; LASER COAGULATION; LASER SURGERY; MACULAR EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA SURGERY; SYSTEMATIC REVIEW; VISUAL ACUITY; VITRECTOMY; BIOMEDICAL TECHNOLOGY ASSESSMENT; COMBINATION DRUG THERAPY; COMPLICATION; DRUG IMPLANT; FACTUAL DATABASE; INTRAVITREAL DRUG ADMINISTRATION; OPHTHALMOLOGY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; RETINAL VEIN OCCLUSION; UNITED STATES;

ACADEMIES AND INSTITUTES; ANGIOGENESIS INHIBITORS; DATABASES, FACTUAL; DEXAMETHASONE; DRUG IMPLANTS; DRUG THERAPY, COMBINATION; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; OPHTHALMOLOGY; RETINAL VEIN OCCLUSION; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES; VISUAL ACUITY;

EID: 85019612594     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2017.03.060     Document Type: Article

References (47)

1. Rogers, S., McIntosh, R.L., Cheung, N., et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117 (2010), 313–319.
2. Mitry, D., Bunce, C., Charteris, D., Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev(1), 2013, CD009510.
3. Koss, M.J., Pfister, M., Rothweiler, F., et al. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol 90 (2012), e98–e103.
4. Aiello, L.P., Avery, R.L., Arrigg, P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (1994), 1480–1487.
5. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98 (1984), 271–282.
6. Park, S.P., Ahn, J.K., Changes of aqueous vascular endothelial growth factor and interleukin-6 after intravitreal triamcinolone for branch retinal vein occlusion. Clin Experiment Ophthalmol 36 (2008), 831–835.
7. Haller, J.A., Bandello, F., Belfort, R. Jr., et al., OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117 (2010), 1134–1146.
8. Lee, J.H., Canny, M.D., De Erkenez, A., et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A 102 (2005), 18902–18907.
9. Wroblewski, J.J., Wells, J.A. 3rd, Adamis, A.P., et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 127 (2009), 374–380.
10. Ferrara, N., Damico, L., Shams, N., et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26 (2006), 859–870.
11. Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004), 391–400.
12. Holash, J., Davis, S., Papadopoulos, N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99 (2002), 11393–11398.
13. Raszewska-Steglinska, M., Gozdek, P., Cisiecki, S., et al. Pars plana vitrectomy with ILM peeling for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 19 (2009), 1055–1062.
14. Fekrat, S., Goldberg, M.F., Finkelstein, D., Laser-induced chorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion. Arch Ophthalmol 116 (1998), 43–52.
15. Bavbek, T., Yenice, O., Toygar, O., Problems with attempted chorioretinal venous anastomosis by laser for nonischemic CRVO and BRVO. Ophthalmologica 219 (2005), 267–271.
16. Oxford Centre for Evidence-Based Medicine - Levels of evidence (March 2009). Available at: http://www.cebm.net/index.aspx?o=1025. Accessed January 31, 2017.
17. Campochiaro, P.A., Heier, J.S., Feiner, L., et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117 (2010), 1102–1112.
18. Brown, D.M., Campochiaro, P.A., Bhisitkul, R.B., et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118 (2011), 1594–1602.
19. Heier, J.S., Campochiaro, P.A., Yau, L., et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119 (2012), 802–809.
20. Campochiaro, P.A., Clark, W.L., Boyer, D.S., et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 122 (2015), 538–544.
21. Clark, W.L., Boyer, D.S., Heier, J.S., et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 123 (2016), 330–336.
22. Scott, I.U., Ip, M.S., VanVeldhuisen, P.C., et al., SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 127 (2009), 1115–1128 Erratum in: Arch Ophthalmol 2009;127:1655.
23. Haller, J.A., Bandello, F., Belfort, R. Jr., et al., OZURDEX GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118 (2011), 2453–2460.
24. Higashiyama, T., Sawada, O., Kakinoki, M., et al. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmol 91 (2013), 318–324.
25. Tadayoni, R., Waldstein, S.M., Boscia, F., et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology 123 (2016), 1332–1344.
26. Donati, S., Barosi, P., Bianchi, M., et al. Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol 22 (2012), 607–614.
27. Moradian, S., Faghihi, H., Sadeghi, B., et al. Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1). Graefes Arch Clin Exp Ophthalmol 249 (2011), 193–200.
28. Ehlers, J.P., Decroos, F.C., Fekrat, S., Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Retina 31 (2011), 1856–1862.
29. Russo, V., Barone, A., Conte, E., et al. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina 29 (2009), 511–515.
30. Parodi, M.B., Iacono, P., Bandello, F., Subthreshold grid laser versus intravitreal bevacizumab as second-line therapy for macular edema in branch retinal vein occlusion recurring after conventional grid laser treatment. Graefes Arch Clin Exp Ophthalmol 253 (2015), 1647–1651.
31. Wroblewski, J.J., Wells, J.A. 3rd, Gonzales, C.R., Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. Am J Ophthalmol 149 (2010), 147–154.
32. Narayanan, R., Panchal, B., Das, T., et al., MARVEL Study Group. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. Br J Ophthalmol 99 (2015), 954–959.
33. Cekic, O., Cakir, M., Yazici, A.T., et al. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Curr Eye Res 35 (2010), 925–929.
34. Guignier, B., Subilia-Guignier, A., Fournier, I., et al. Prospective pilot study: efficacy of intravitreal dexamethasone and bevacizumab injections in the treatment of macular oedema associated with branch retinal vein occlusion. Ophthalmologica 230 (2013), 43–49.
35. Singer, M., Tan, C.S., Bell, D., Sadda, S.R., Area of peripheral retinal nonperfusion and treatment response in branch and central retinal vein occlusion. Retina 34 (2014), 1736–1742.
36. Campochiaro, P.A., Hafiz, G., Mir, T.A., et al. Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE Trial. Ophthalmology 122 (2015), 1426–1437.
37. Chung, E.J., Lee, H., Koh, H.J., Arteriovenous crossing sheathotomy versus intravitreal triamcinolone acetonide injection for treatment of macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246 (2008), 967–974.
38. Kumagai, K., Furukawa, M., Ogino, N., et al. Long-term outcomes of vitrectomy with or without arteriovenous sheathotomy in branch retinal vein occlusion. Retina 27 (2007), 49–54.
39. Mason, J. 3rd, Feist, R., White, M. Jr., et al. Sheathotomy to decompress branch retinal vein occlusion: a matched control study. Ophthalmology 111 (2004), 540–545.
40. Avci, R., Inan, U.U., Kaderli, B., Evaluation of arteriovenous crossing sheathotomy for decompression of branch retinal vein occlusion. Eye (Lond) 22 (2008), 120–127.
41. Chen, H.C., Wiek, J., Gupta, A., et al. Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion. Br J Ophthalmol 82 (1998), 162–167.
42. Fekrat, S., Shea, A.M., Hammill, B.G., et al. Resource use and costs of branch and central retinal vein occlusion in the elderly. Curr Med Res Opin 26 (2010), 223–230.
43. Quigley, H.A., Cassard, S.D., Gower, E.W., et al. The cost of glaucoma care provided to Medicare beneficiaries from 2002 to 2009. Ophthalmology 120 (2013), 2249–2257.
44. Martin, D.F., Maguire, M.G., Ying, G.S., et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364 (2011), 1897–1908.
45. Smiddy, W.E., Economic considerations of macular edema therapies. Ophthalmology 118 (2011), 1827–1833.
46. Chang, M.A., Fine, H.F., Bass, E., et al. Patients’ preferences in choosing therapy for retinal vein occlusions. Retina 27 (2007), 789–797.
47. Varma, R., Bressler, N.M., Suñer, I., et al., BRAVO and CRUISE Study Groups. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology 119 (2012), 2108–2118.